Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Alx Oncology Holdings Inc (ALXO)
Alx Oncology Holdings Inc (ALXO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 799,595
  • Shares Outstanding, K 49,819
  • Annual Sales, $ 0 K
  • Annual Income, $ -123,480 K
  • 60-Month Beta 1.65
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.96
Trade ALXO with:

Options Overview Details

View History
  • Implied Volatility 115.84% ( +40.19%)
  • Historical Volatility 70.34%
  • IV Percentile 81%
  • IV Rank 52.17%
  • IV High 216.96% on 03/22/23
  • IV Low 5.55% on 09/26/23
  • Put/Call Vol Ratio 999.99
  • Today's Volume 21
  • Volume Avg (30-Day) 105
  • Put/Call OI Ratio 0.17
  • Today's Open Interest 1,851
  • Open Int (30-Day) 3,503

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -0.84
  • Number of Estimates 5
  • High Estimate -0.68
  • Low Estimate -1.06
  • Prior Year -0.75
  • Growth Rate Est. (year over year) -12.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.36 +18.64%
on 02/09/24
17.42 -9.01%
on 02/15/24
+2.26 (+16.63%)
since 01/23/24
3-Month
7.35 +115.65%
on 12/01/23
17.42 -9.01%
on 02/15/24
+6.64 (+72.10%)
since 11/22/23
52-Week
3.94 +302.72%
on 08/31/23
17.42 -9.01%
on 02/15/24
+8.88 (+127.40%)
since 02/23/23

Most Recent Stories

More News
Why ALX Oncology Stock Is Skyrocketing Today

Investors are cheering the immuno-oncology company's latest clinical trial results.

ALXO : 15.85 (-1.25%)
Stock Index Futures Plunge Ahead of U.S. JOLTs Report, U.S. Rates Stay in Focus

December S&P 500 futures (ESZ23) are down -0.38%, and December Nasdaq 100 E-Mini futures (NQZ23) are down -0.50% this morning as market participants looked ahead to the release of fresh labor market data...

ESZ23 : 4,694.27s (-0.58%)
NQZ23 : 16,530.23s (-0.07%)
NVDA : 788.17 (+0.36%)
META : 484.03 (-0.43%)
GOOGL : 143.96 (-0.09%)
PODD : 184.21 (-6.56%)
K : 56.43 (-0.97%)
TGT : 151.48 (+0.76%)
BOO.LN : 36.100 (+0.64%)
ZAL.D.DX : 19.345 (+0.42%)
ALXO : 15.85 (-1.25%)
ODD : 38.97 (-1.02%)
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation

NetworkNewsWire Editorial Coverage : More than 30 million people in the United States suffer with a rare disease; most of them are receiving no current treatment. Supporting the development and evaluation...

GNPX : 4.36 (-0.91%)
RHHBY : 32.9600 (+1.45%)
JAZZ : 132.28 (+2.98%)
ALXO : 15.85 (-1.25%)
ACHL : 1.3600 (unch)
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation

NetworkNewsWire Editorial Coverage : More than 30 million people in the United States suffer with a rare disease; most of them are receiving no current treatment. Supporting the development and evaluation...

GNPX : 4.36 (-0.91%)
RHHBY : 32.9600 (+1.45%)
JAZZ : 132.28 (+2.98%)
ALXO : 15.85 (-1.25%)
ACHL : 1.3600 (unch)
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation

EQNX::TICKER_START (NASDAQ:GNPX),(OTCQX:RHHBY),(NASDAQ:JAZZ),(NASDAQ:ALXO),(NASDAQ:ACHL) EQNX::TICKER_END

GNPX : 4.36 (-0.91%)
RHHBY : 32.9600 (+1.45%)
JAZZ : 132.28 (+2.98%)
ALXO : 15.85 (-1.25%)
ACHL : 1.3600 (unch)
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation

/PRNewswire/ -- More than 30 million people in the United States suffer with a rare disease; most of them are receiving no current treatment. Supporting the...

RHHBY : 32.9600 (+1.45%)
GNPX : 4.36 (-0.91%)
JAZZ : 132.28 (+2.98%)
ALXO : 15.85 (-1.25%)
ACHL : 1.3600 (unch)
ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Combination with Cetuximab and Pembrolizumab in Patients with Advanced Colorectal Cancer

SOUTH SAN FRANCISCO, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage...

ALXO : 15.85 (-1.25%)
ALX Oncology Reports Second Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage...

ALXO : 15.85 (-1.25%)
ALX Oncology’s Evorpacept Receives Fast Track Designation from FDA as First-Line Treatment for Head and Neck Squamous Cell Carcinoma

SOUTH SAN FRANCISCO, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage...

ALXO : 15.85 (-1.25%)
Merck (MRK) Q2 Earnings & Revenues Top, COVID Drug Helps Sales

Merck (MRK) beats on Q2 estimates for earnings and sales. The company continues to see robust growth in COVID drug sales and Keytruda and Gardasil sales.

AZN : 65.83 (+2.65%)
MRK : 129.45 (+0.15%)
DTIL : 13.29 (+9.20%)
ALXO : 15.85 (-1.25%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

ALX Oncology Holdings Inc.is a clinical-stage immuno-oncology company. It focuses on developing therapies for patients fighting cancer. The company's product candidate consist ALX148, which is in clinical stage. ALX Oncology Holdings Inc.is based in Burlingame, California.

See More

Key Turning Points

3rd Resistance Point 16.84
2nd Resistance Point 16.56
1st Resistance Point 16.21
Last Price 15.85
1st Support Level 15.58
2nd Support Level 15.30
3rd Support Level 14.95

See More

52-Week High 17.42
Last Price 15.85
Fibonacci 61.8% 12.27
Fibonacci 50% 10.68
Fibonacci 38.2% 9.09
52-Week Low 3.94

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar